Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease

Nature Medicine

Volumn 8, Issue 12, 2002, Pages 1405-1413

  Sun, Yonglian ^a   Chen, Helen M ^a   Subudhi, Sumit K ^a   Chen, Jonathan ^a   Koka, Rima ^a   Chen, Lieping ^b   Fu, Yang Xin ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; GAMMA INTERFERON; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD137; UNCLASSIFIED DRUG;

ALLOGRAFT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CONTROLLED STUDY; CORRELATION ANALYSIS; GRAFT REJECTION; INTERFERON PRODUCTION; LYMPHADENOPATHY; LYMPHOCYTE SUBPOPULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION;

ANIMALIA;

EID: 0036913169     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1202-796     Document Type: Article

References (43)

1. Theofilopoulos, A.N. & Dixon, F.I. Etiopathogenesis of murine SLE. Immunol. Rev. 55, 179-216 (1981).
2. Cohen, P.L. & Eisenberg, R.A. Lpr and gld: Single gene models of systemic autoimmunity and lymphoproliferative disease. Annu. Rev. Immunol. 9, 243-269 (1991).
3. Wofsy, D., Hardy, R.R. & Seaman, W.E. The proliferating cells in autoimmune MRL/lpr mice lack L3T4, an antigen on "helper" T cells that is involved in the response to class II major histocompatibility antigens. J. Immunol. 132, 2686-2689 (1984).
4. Morse, H.C. 3rd et al. Abnormalities induced by the mutant gene lpr: Expansion of a unique lymphocyte subset. J. Immunol. 129, 2612-2615 (1982).
5. Andrews, B.S. et al. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J. Exp. Med. 148, 1198-1215 (1978).
6. Kaliyaperumal, A., Michaels, M.A. & Datta, S.K. Antigen-specific therapy of murine lupus nephritis using nucleosomal peptides: Tolerance spreading impairs pathogenic function of autoimmune T and B cells. J. Immunol. 162, 5775-5783 (1999).
7. Wofsy, D. Treatment of murine lupus with anti-CD4 monoclonal antibodies. Immunol. Ser. 59, 221-236 (1993).
8. Mohan, C., Shi, Y., Laman, J.D. & Datta, S.K. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J. Immunol. 154, 1470-80 (1995).
9. Finck, B.K., Linsley, P.S. & Wofsy, D. Treatment of murine lupus with CTLA4Ig. Science 265, 1225-1227 (1994).
10. Kalled, S.L., Cutler, A.H., Datta, S.K. & Thomas, D.W. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: Preservation of kidney function. J. Immunol. 160, 2158-2165 (1998).
11. Liang, B., Kashgarian, M.J., Sharpe, A.H. & Mamula, M.I. Autoantibody responses and pathology regulated by B7-1 and B7-2 costimulation in MRL/lpr lupus. J. Immunol. 165, 3436-3443 (2000).
12. Theofilopoulos, A.N. & Lawson, B.R. Tumour necrosis factor and other cytokines in murine lupus. Ann. Rheum. Dis. 58 Suppl. 1, 149-55 (1999).
13. Kelley, V.R. & Wuthrich, R.P. Cytokines in the pathogenesis of systemic lupus erythematosus. Semin. Nephrol. 19, 57-66 (1999).
14. Lawson, B.R. et al. Treatment of murine lupus with cDNA encoding IFN-γR/Fc. J. Clin. Invest. 106, 207-215 (2000).
15. Vinay, D.S. & Kwon, B.S. Role of 4-1BB in immune responses. Semin. Immunol. 10, 481-489 (1998).
16. Kwon, B., Moon, C.H., Kang, S., Seo, S.K. & Kwon, B.S. 4-1BB: Still in the midst of darkness. Mol. Cells 10, 119-126 (2000).
17. Pollok, K.E. et al. Inducible T cell antigen 4-1BB. Analysis of expression and function. J. Immunol. 150, 771-781 (1993).
18. Melero, I., Johnston, J.V., Shufford, W.W., Mittler, R.S. & Chen, L. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell. Immunol. 190, 167-172 (1998).
19. Goodwin, R.G. et al. Molecular cloning of a ligand for the inducible T cell gene 4-1BB: A member of an emerging family of cytokines with homology to tumor necrosis factor. Eur. J. Immunol. 23, 2631-2641 (1993).
20. Pollok, K.E. et al. 4-1BB T-cell antigen binds to mature B cells and macrophages, and costimulates anti-μ-primed splenic B cells. Eur. J. Immunol. 24, 367-374 (1994).
21. Alderson, M.R. et al. Molecular and biological characterization of human 4-1BB and its ligand. Eur. J. Immunol. 24, 2219-2227 (1994).
22. Melero, I. et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nature Med. 3, 682-685 (1997).
23. + T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J. Exp. Med. 186, 47-55 (1997).
24. Blazar, B.R. et al. Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients. J. Immunol. 166, 3174-3183 (2001).
25. Wilcox, R. et al. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J. Clin. Invest. 109, 651-659 (2002).
26. + T cell responses. Nature Immunol. 3, 536-541 (2002).
27. Mittler, R.S., Bailey, T.S., Klussman, K., Trailsmith, M.D. & Hoffmann, M.K. Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy. J. Exp. Med. 190, 1535-1540 (1999).
28. Sun, Y. et al. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J. Immunol. 168, 1457-1465 (2002).
29. Adachi, M., Watanabe-Fukunaga, R. & Nagata, S. Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice. Proc. Natl. Acad. Sci. USA 90, 1756-1760 (1993).
30. Suda, T. & Nagata, S. Why do defects in the Fas-Fas ligand system cause autoimmunity? J. Allergy Clin. Immunol. 100, S97-101 (1997).
31. Hildeman, D.A. et al. Reactive oxygen species regulate activation-induced T cell apoptosis. Immunity 10, 73S-744 (1999).
32. Ding, A.H., Nathan, C.F. & Stuehr, D.J. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J. Immunol. 141, 2407-2412 (1988).
33. Williams, M.S., Noguchi, S., Henkart, P.A. & Osawa, Y. Nitric oxide synthase plays a signaling role in TCR-triggered apoptotic death. J. Immunol. 161, 6526-6531 (1998).
34. Haendeler, J., Zeiher, A.M. & Dimmeler, S. Nitric oxide and apoptosis. Vitam. Horm. 57, 49-77 (1999).
35. Passwell, J., Schreiner, G.F., Nonaka, M., Beuscher, H.U. & Colten, H.R. Local extrahepatic expression of complement genes C3, factor 8, C2, and C4 is increased in murine lupus nephritis. J. Clin. Invest. 82, 1676-1684 (1988).
36. Hoffman, R.W. T cells in the pathogenesis of systemic lupus erythematosus. Front Biosci. 6, D1369-1378 (2001).
37. Jacobson, B.A., Rothstein, T.L. & Marshak-Rothstein, A. Unique site of IgG2a and rheumatoid factor production in MRL/lpr mice. Immunol. Rev. 156, 103-110 (1997).
38. Peng, S.L., Moslehi, J. & Craft, J. Roles of interferon-γ and interleukin-4 in murine lupus. J. Clin. Invest. 99, 1936-1946 (1997).
39. Balomenos, D., Rumold, R. & Theofilopoulos, A.N. Interferon-γ is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J. Clin. Invest. 101, 364-371 (1998).
40. Haas, C., Ryffel, B. & Le Hir, M. IFN-γ is essential for the development of autoimmune glomerulonephritis in MRL/lpr mice. J. Immunol. 158, 5484-5491 (1997).
41. Schwarting, A., Wada, T., Kinoshita, K., Tesch, G. & Kelley, V.R. IFN-γ receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice. J. Immunol. 161, 494-503 (1998).
42. Nicoletti, F. et al. Dichotomic effects of IFN-γ on the development of systemic lupus erythematosus-like syndrome in MRL-lpr/lpr mice. Eur. J. Immunol. 30, 438-447 (2000).
43. Wang, J. et al. The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT. J. Clin. Invest. 108, 1771-1780 (2001).